Every round on record, with the sources behind each and the investors on them.
Magnitude Biosciences specializes in whole-organism high-throughput screening technologies and assays for drug discovery, serving clients in the biotech, pharma, and academic sectors.
magnitudebiosciences.comLinkedInDurham, UKBiotechFounded 201819 people
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source separately mentions matched grant funding from Innovate UK; it is not included as an investor.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source separately mentions a further £217,000 Innovate UK Investor Partnership grant; this is not included in the funding-round amount.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The headline writes £250k, while the article body writes £250,000; the body’s explicit figure is used. No headquarters is stated.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $948K over £700,000 | 2025-05-27 | NPIF II, Finance Durham Fund | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source separately mentions matched grant funding from Innovate UK; it is not included as an investor. | ||||
Magnitude Biosciences is a specialist contract research organisation that helps industry and academia progress research through expert scientists, C. elegans services and automated imaging technology.
Magnitude addresses the limits and cost of cell-based and mammalian preclinical testing by using C. elegans, automated imaging and whole-organism data to produce richer efficacy, toxicity and mechanism-of-action readouts in weeks. Its £1.3 million 2026 investment is funding VivoScan's commercialisation and the ambition to screen millions of compounds, building on more than 120 delivered projects and earlier demand from pharma and biotech clients.
Checked against 10 sources today
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.6M £1.3 million | 2023-09-25 | Northstar Ventures | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source separately mentions a further £217,000 Innovate UK Investor Partnership grant; this is not included in the funding-round amount. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: distilledpost.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
| Seed Seed Follow On [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $328K £250k | 2020-08-21 | Future Fund | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The headline writes £250k, while the article body writes £250,000; the body’s explicit figure is used. No headquarters is stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: uktechnews.info·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Investment | £250k | 2023-04 | Northstar Ventures, Saker Capital LLP | |
| Investment | £225k | 2019-09 | Northstar Ventures, Saker Capital LLP | |
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: UK Government Future Fund, Maven Capital Partners, Innovate UK, Northern Accelerator, British Business Bank